Abstract
Mesothelioma of the peritoneum is a distinct entity that requires multidisciplinary care to improve oncological outcomes. In this article, we review the current management strategies discussed at the PSOGI meeting in Washington DC 2016 and provide evidence based recommendations for diagnosis and management of this disease.
Keywords:
Mesothelioma of the peritoneum is a distinct entity from mesothelioma of the pleura in its etiopathogenesis and pathophysiology. While relatively infrequent with an estimated incidence of 500–800 new cases per year in the United States, it can be debilitating for patients due to development of bowel obstructions, inanition and death [Citation1]. At the recent peritoneal surface oncology group international (PSOGI) meeting held in Washington D.C. 2016, a roundtable was held and this article summarises some of the strategies in the management of peritoneal mesothelioma.
Recommendation 1
Antecedent exposure factors including asbestos exposure, previous radiation and smoking should be ascertained in addition to a thorough history.
BAP-1 germline testing should be considered for families with clustering of disease.
Genetic association of peritoneal mesothelioma with BRCA-1 associated protein (BAP-1) has been suggested in small studies [Citation3]. While deletions of BAP-1 region are found in several peritoneal mesothelioma tissue samples, these are not always germ-line mutations. Potentiation of the carcinogenic effect of asbestos has been suggested in families with germline BAP-1 deletions and may play a role in the etiopathogenesis of this disease.
Recommendation 2
Histological diagnosis of a peritoneal mesothelioma must be reviewed by an expert pathologist.
Synoptic reporting on histological subtype (well differentiated papillary, multicystic, epithelioid, biphasic and sarcomatoid), invasiveness (necrosis, Ki-67, mitotic rate) and nodal status (if available) is recommended.
Pathological examination of a mesothelioma is essential for diagnosis and characterisation. Laparoscopic or percutaneous biopsy provides adequate tissue in most cases. Immunohistochemistry is essential to confirm diagnosis. Histological differentiation into papillary, multicystic (benign variants) and epithelioid, biphasic and sarcomatoid is critical for decision making. Synoptic reporting including necrosis, grade and mitotic count can also help with prognostication. Ki-67 has been shown to be a prognostic marker for outcomes for patients undergoing surgery and may be considered [Citation4,Citation5].
Recommendation 3
Serum tumour markers such as CA-125, CA-19-9, CA 15.3, fibulin-3 and Mesothelin may be obtained to detect disease and therapy course.
Recommendation 4
High quality cross sectional imaging modalities such as multi-slice CT scan, and/or diffusion weighted MRI must be obtained to assess burden of disease.
The use of PET scan in detecting nodal disease has been described but is not routinely indicated [Citation8].
Recommendation 5
All patient with peritoneal mesothelioma must be evaluated at a peritoneal malignancy specialty centre with access to peritoneal surgeons experienced in the techniques of cytoreductive surgery and medical oncologists with access to clinical trials.
Recommendation 6
Patients with malignant epithelioid mesothelioma that are resectable should be offered cytoreductive surgery and HIPEC.
HIPEC with platinum based agents such as cisplatin, and carboplatin either alone or in combination with doxorubicin, pemetrexed, ifosfoamide and mitomycin have been used [Citation13]. Single agent mitomycin has also been used with similar efficacy although slightly inferior survival outcomes. Normothermic intraperitoneal chemotherapy with pemetrexed and other agents have also been considered demonstrating significantly improved survival in patients [Citation14]. HIPEC has been independently correlated with improved survival even in the setting of an incomplete cytoreduction, and to control malignant ascites [Citation15].
Recommendation 7
Patients with well differentiated papillary and multicystic mesothelioma may be offered observation, cytoreduction only, or cytoreduction with HIPEC depending on disease course.
The disease biology of both these histologies is considered relatively indolent and can generally be safely observed unless the disease course, imaging characteristics or symptoms of a patient suggest otherwise [Citation16]. The incremental benefit of HIPEC in this setting is unknown.
Recommendation 8
Patients with biphasic, sarcomatoid or unresectable disease may be considered for systemic chemotherapy, clinical trials or cytoreductive surgery and HIPEC after a careful multidisciplinary fashion.
Patients with biphasic and sarcomatoid histology perform rather poorly with surgery although a small subset of patients benefit from cytoreductive surgery and HIPEC as well [Citation15]. Such patients are best served in clinical trials with novel agents. The association of high Ki67 and high PCI defined a subset of patients with unsatisfactory results after CRS HIPEC [Citation4]. In patients with unresectable disease, the use of systemic therapy with a neoadjuvant intent has not been shown to improve survival but anecdotally has been shown to lead to clinical responses that might then lead to a more complete cytoreduction [Citation17]. While such a strategy has been used often in practice, evidence supporting the same needs to be accrued.
Recommendation 9
The effectiveness of adjuvant chemotherapy for patients with malignant peritoneal mesothelioma is currently unknown and may be used after careful multidisciplinary consideration.
Recommendation 10
All patients with peritoneal mesothelioma must be considered for inclusion in clinical trials, registries or both.
In summary, we recommend multidisciplinary management for patients with peritoneal mesotheliomas that may offer such patients improved oncological and patient reported outcomes.
Disclosure statement
Dr. Kiran Turaga has received honoraria from CARIS Biosciences and CASTLE Biosciences.
References
- Miura JT, Johnston FM, Gamblin TC, et al. (2014). Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol 21:3947–53.
- Lin RT, Takahashi K, Karjalainen A, et al. (2007). Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369:844–9.
- Leblay N, Lepretre F, Le Stang N, et al. (2017). BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 12:724--33.
- Kusamura S, Torres Mesa PA, Cabras A, et al. (2016). The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23:1468–73.
- Lee M, Alexander HR, Burke A. (2013). Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology 45:464–73.
- Pass HI, Levin SM, Harbut MR, et al. (2012). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367:1417–27.
- Arnold DT, De Fonseka D, Hamilton FW, et al. (2017). Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 116:731--41.
- Cao Q, Lu M, Heath J, et al. (2012). 18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clin Nucl Med 37:492–4.
- Rajeev R, Klooster B, Turaga KK. (2016). Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol 7:122–8.
- Alexander HR Jr. (2010). Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 17:21–2.
- Alexander HR Jr, Bartlett DL, Pingpank JF, et al. (2013). Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153:779–86.
- Sugarbaker PH, Turaga KK, Alexander HR Jr, et al. (2016). Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract 12:928–35.
- Helm JH, Miura JT, Glenn JA, et al. (2015). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22:1686–93.
- Sugarbaker PH, Chang D. (2017). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol pii: S0748--7983(17):30059--8.
- Yan TD, Deraco M, Baratti D, et al. (2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42.
- Kindler HL. (2013). Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book 182–8. doi:10.1200/EdBook_AM.2013.33.182
- Kepenekian V, Elias D, Passot G, et al. (2016). Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 65:69–79.
- Stahel RA, Riesterer O, Xyrafas A, et al. (2015). Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–8.